Roche - Latest News [Page 1]
Patients With Haemophilia And Multiple Sclerosis Set To Benefit From Roche’s Latest Multimedicine Agreement With Pharmac
Monday, 4 September 2023, 12:32 pm | Roche
People with haemophilia A and multiple sclerosis are set to benefit from a multi-medicine funding agreement between Pharmac and Roche Products (NZ), confirmed today. This agreement will significantly expand access to these treatments from 1 October 2023. ... More >>
Roche Congratulates PHARMAC For Proposing To Fund New Treatments For Lung Cancer
Friday, 16 December 2022, 8:59 am | Roche
Roche Products (New Zealand) General Manager Alex Muelhaupt today congratulated PHARMAC for proposing to fund new treatments for lung cancer. PHARMAC has reached provisional agreement with Roche to fund its immunotherapy Tecentriq (atezolizumab) ... More >>
Pharmac Review Important First Step, Shows Medicines Crisis Is Real
Wednesday, 1 June 2022, 12:08 pm | Roche
Roche Products (New Zealand) General Manager Alex Muelhaupt today congratulated the Pharmac External Review Committee and the Government for their courage in identifying shortcomings in Pharmac’s operations and their intention to improve them, particularly ... More >>
Otago Scientists Win National Award For Cancer Research
Monday, 23 November 2020, 10:54 am | Roche
A University of Otago researcher and a colorectal surgeon have won the 2020 NZ Society for Oncology (NZSO) Roche Translational Cancer Research Fellowship to advance knowledge of how inflammatory bowel disease (IBD) related colorectal cancer develops, and ultimately ... More >>
New Medicine Funding Offers Hope For Kiwis Living With Rare Blood Disorder
Wednesday, 11 November 2020, 10:53 am | Roche
New Zealanders living with a rare blood disorder which can cause spontaneous, fatal internal bleeding and excruciating arthritis-like symptoms are set to benefit from the funding of a new medicine named Hemlibra® (emicizumab) from December 1, 2020. ... More >>
Oncologist Urges Kiwi Lung Cancer Patients to be Screened
Sunday, 10 November 2019, 12:15 pm | Roche
An oncologist is urging hundreds of Kiwi lung cancer patients to contact their doctor to ensure they are screened for a rare form of the disease, which can now be treated for free, under a new initiative. More >>
Otago scientist wins national award for cancer research
Tuesday, 29 October 2019, 9:21 am | Roche
University of Otago gastrointestinal cancer researcher and medical oncologist, Dr Sharon Pattison, has won the 2019 NZSO (NZ Society for Oncology) Roche Translational Cancer Research Fellowship to drive the discovery of novel treatments, translate ... More >>
New Drug Offers Hope for Kiwis Living With Rare Disorder
Tuesday, 18 December 2018, 10:53 am | Roche
New Zealanders living with a rare blood disorder which can cause spontaneous, fatal internal bleeding and excruciating arthritis-like symptoms are set to benefit from the Medsafe registration of a new medicine. More >>
Scientist wins national award for cancer research
Saturday, 25 August 2018, 12:17 pm | Roche
University of Otago, Christchurch scientist Dr Andrew Das has won the 2018 NZSO (NZ Society of Oncologists) Roche NZ Translational Cancer Research Fellowship to learn techniques and bioinformatic analyses that will further his work as part of a research ... More >>
Cancer patients gain in Roche’s new multi-medicine agreement
Monday, 5 December 2016, 12:46 pm | Roche
Cancer patients are among those who will benefit from an innovative multi-medicine funding agreement between Pharmac and Roche Products (NZ), announced today. More than 2,000 New Zealand patients, most with life-threatening illnesses, are expected ... More >>
Targeted therapies for patients with advanced melanoma
Wednesday, 9 March 2016, 3:40 pm | Roche
March 9, 2016: Targeted therapies called BRAF inhibitors may offer patients with BRAF V600 mutation-positive advanced melanoma the possibility of longer survival. However, PHARMAC has so far declined to fund them in New Zealand. More >>
Setting the record straight on Herceptin
Monday, 14 December 2015, 11:04 am | Roche
Roche Products NZ dismisses Health Minister Jonathan Coleman’s statement on TV3’s Paul Henry show on Friday, December 11 suggesting that a nine-week course of Herceptin® (trastuzumab) is “just as good as a 52-week” course. Medsafe has not approved ... More >>
More Effective Treatment is Available for Women
Tuesday, 7 October 2014, 4:20 pm | Roche
International study confirms a more effective treatment is available for women with advanced HER2-positive breast cancer More >>
Daily capsule for patients with skin cancer
Wednesday, 23 April 2014, 11:47 am | Roche
Erivedge® (vismodegib), a new medicine that has been shown to help patients with a disfiguring and potentially life-threatening form of skin cancer, is now registered for use in New Zealand More >>
Tarceva Funded First Line for Non-Small Cell Lung Cancer
Thursday, 9 January 2014, 9:39 am | Roche
New Zealanders with a specific type of advanced Non-Small Cell Lung Cancer (NSLC) can now receive funded first line treatment with Tarceva, an anti-cancer medicine from Roche Products. More >>
Two new treatments for breast cancer registered in NZ
Monday, 14 October 2013, 11:10 am | Roche
Two new treatments for advanced HER2-positive breast cancer registered in New Zealand First line treatment PERJETA® and second line treatment KADCYLA® extend and improve the quality of life of patients with advanced HER2-positive breast cancer 14 October ... More >>
Roche NZ welcomes Herceptin duration trial results
Tuesday, 2 October 2012, 10:36 am | Roche
Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. [1,2] The studies were ... More >>
Leukaemia patients to benefit as treatment
Thursday, 28 July 2011, 1:33 pm | Roche
New Zealanders with chronic lymphocytic leukaemia (CLL), an incurable form of white blood cell cancer, can now receive funded treatment with MabThera® (rituximab) a leading-edge biotherapy. From 1 August MabThera will be funded for use in combination ... More >>
Roche welcomes Health Select Committee report
Wednesday, 8 June 2011, 12:07 pm | Roche
Roche Products New Zealand welcomes today’s release of the Health Select Committee’s report as a milestone opportunity for New Zealand to become recognised as a world leader in clinical research. The report soundly documents the steps that need to ... More >>
Roche sponsors summer student in arthritis research project
Wednesday, 19 January 2011, 11:43 am | Roche
The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche. The project will see a research student review treatment outcomes for patients with arthritis who have been treated with ... More >>